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H I G H L I G H T S
 Piperazine derivatives presented cytotoxicity, being TFMPP the most cytotoxic.
 Piperazine designer drugs signiﬁcantly increased Ca2+ intracellular levels.
 All drugs caused decreased intracellular ATP and mitochondrial membrane potential.
 Mitochondrial permeability transition pore seems to play a role in cytoxicity.
 There were found early apoptotic cells and cells undergoing secondary necrosis.
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A B S T R A C T
Abuse of synthetic drugs is widespread among young people worldwide. In this context, piperazine
derived drugs recently appeared in the recreational drug market. Clinical studies and case-reports
describe sympathomimetic effects including hypertension, tachycardia, and increased heart rate. Our
aim was to investigate the cytotoxicity of N-benzylpiperazine (BZP), 1-(3-triﬂuoromethylphenyl)
piperazine (TFMPP), 1-(4-methoxyphenyl) piperazine (MeOPP), and 1-(3,4-methylenedioxybenzyl)
piperazine (MDBP) in the H9c2 rat cardiac cell line. Complete cytotoxicity curves were obtained at a 0–
20 mM concentration range after 24 h incubations with each drug. The EC50 values (mM) were 343.9, 59.6,
570.1, and 702.5 for BZP, TFMPP, MeOPP, and MDBP, respectively. There was no change in oxidative stress
markers. However, a decrease in total GSH content was noted for MDBP, probably due to metabolic
conjugation reactions. All drugs caused signiﬁcant decreases in intracellular ATP, accompanied by
increased intracellular calcium levels and a decrease in mitochondrial membrane potential that seems to
involve the mitochondrial permeability transition pore. The cell death mode revealed early apoptotic
cells and high number of cells undergoing secondary necrosis. Among the tested drugs, TFMPP seems to
be the most potent cytotoxic compound. Overall, piperazine designer drugs are potentially cardiotoxic
and support concerns on risks associated with the intake of these drugs.
ã 2014 Elsevier Ireland Ltd. All rights reserved.
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Piperazine designer drugs emerged in the drug market for
recreational purposes in the early 2000s. They can be divided* Corresponding author. Tel.: +351 220428597.
E-mail addresses: m.arbo@terra.com.br, marcelo.arbo@gmail.com (M.D. Arbo).
http://dx.doi.org/10.1016/j.toxlet.2014.06.031
0378-4274/ã 2014 Elsevier Ireland Ltd. All rights reserved.into two classes, the benzylpiperazines such as N-benzylpiper-
azine (BZP) and its methylenedioxy-analogue 1-(3,4-methylene-
dioxybenzyl) piperazine (MDBP), and the phenylpiperazines such
as 1-(3-chlorophenyl) piperazine (m CPP), 1-(4-ﬂuorophenyl)
piperazine (p FPP), 1-(3-triﬂuoromethylphenyl) piperazine
(TFMPP), and 1-(4-methoxyphenyl) piperazine (MeOPP)
(Fig. 1). Generally, they are consumed as capsules, tablets or
pills but also in powder or liquid forms (Gee et al., 2005) under
Fig. 1. Chemical structure of some piperazine designer drugs.
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“Herbal ecstasy,” “A2,” “Legal X,” “Legal E,” or simply party pills.
They can also appear as adulterants of MDMA and cocaine
(Staack et al., 2007).
In humans, piperazines are readily absorbed from the
gastrointestinal tract (Antia et al., 2009; Schep et al., 2011). The
information available on blood concentrations and pharmacoki-
netic distribution data is extremely limited. Blood concentrations
measured at clinical studies with human volunteers reached
approximately 1 mM after 200 mg of orally administrated BZP
(Antia et al., 2009) and 0.1 mM after 60 mg of TFMPP (Antia et al.,
2010). However, higher (up to 25 times) and largely discrepant
blood concentrations were reported after intoxication with BZP
and TFMPP (Gee et al., 2008; Kovaleva et al., 2008; Wood et al.,
2008; Antia et al., 2009, 2010; Gee et al., 2010). Moreover, it is
known that piperazine designer drugs readily cross the blood–
brain barrier and interestingly, animal studies have shown that the
TFMPP Cmax brain-to-blood concentration ratio was in excess of
one order of magnitude (Schep et al., 2011) indicating that these
drugs achieve high tissue concentrations. The piperazine designer
drugs are mainly metabolized in the liver, being the phenyl-
piperazines more extensively metabolized than the benzylpiper-
azines, and excreted almost exclusively as metabolites (Maurer
et al., 2004). The main metabolic pathways that were already
described for the piperazine designer drugs in animals and in
humans are the aromatic hydroxylation of BZP (Staack and Maurer,
2005), TFMPP (Staack et al., 2003), and MeOPP (Staack et al., 2004),
and the demethylenation of MDBP (Staack and Maurer, 2004). Therates of urinary excretion of the drugs and metabolites seem to
vary widely among individuals (Austin and Monasterio, 2004).
Phenylpiperazine designer drugs, such as TFMPP, are non-
selective 5-HT agonists, and also act as substrates for serotonin
transporters (SERTs). On the other hand, benzylpiperazine
derivatives, namely BZP, act on central dopaminergic substrates
such as D1-like receptors and dopamine transporters (DATs). It has
been reported that the combined use of BZP and TFMPP in pills
(mixed at a 2:1 ratio, in most cases) mimics the effects of 3,4-
methylenedioxymethamphetamine (MDMA, ecstasy) in humans.
It is, therefore, believed that this combination aggregates the
stimulant effect of BZP, through its dopaminergic action, with the
hallucinogenic effects of TFMPP, via serotonergic activation (for
review see Arbo et al., 2012).
Accordingly, cardiovascular effects dependent on both dopami-
nergic and serotonergic stimulation were noted after the intake of
piperazine designer drugs, and a predominance of adrenergic
effects in the peripheral system, characteristic of a sympathomi-
metic toxindrome, was observed (Schep et al., 2011). Most
common effects include d-amphetamine-like effects (Lin et al.,
2011), tachycardia, hypertension, anxiety, vomiting, headache,
migraine, palpitations, confusion, collapse, and seizure (Gijsman
et al., 1998; Gee et al., 2005; Feuchtl et al., 2004; Thompson et al.,
2010). In a randomized, double-blind, placebo-controlled study, a
single administration of 200 mg BZP to women induced an increase
in systolic and diastolic blood pressure and heart rate comparing to
placebo (Lin et al., 2009). The same cardiovascular effects were
found in other studies using a single administration of a BZP/
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et al. (2008) reported a case of three male young adults presenting
dissociative symptoms, agitation with bruxism, nausea, and
features of sympathomimetic toxicity, with dilated pupils and
tachycardia after the intake of four tablets of a drug thought to be
ecstasy but contaning BZP and TFMPP. In New Zealand, two cases
involving an adult woman and a young man were reported, in
which the patients developed status epilepticus, hyperthermia,
tachycardia, and tachypnea after BZP intake (Gee et al., 2010). In a
non-fatal case of mCPP overdose, a female patient developed
anxiety, agitation, drowsiness, ﬂushing, visual disturbances, and
tachycardia (Kovaleva et al., 2008).
The cardiovascular effects of recreational drugs are, to some
extent, predictable because the receptors and transporters on
which they act are located both in the central nervous system and
in the periphery. Drugs acting on serotonergic, dopaminergic, or
noradrenergic systems are, therefore, likely to induce vasocon-
striction and/or tachycardia and arrhythmia. Extreme activation of
the sympathetic control of the cardiovascular system can lead to
profound vasoconstriction and ischemia. The resultant hyperten-
sion is a risk factor for strokes and myocardial infarcts, which are
more common in chronic sympathomimetic drug abusers. The
cardiac effect of sympathetic stimulation produces both ischemia
(coronary vasoconstriction) and an increased oxygen demand (as a
consequence of increased myocardial contractility). Sympathomi-
metic drugs also induce arrhythmias, which probably contribute to
fatalities (Dawson and Moffatt, 2012).
Besides the activation of central and peripheral neurotransmis-
sion, these drugs may act directly at the cardiomyocyte level to
produce cytotoxicity. This has been noted for example with the
cardiotoxicity mechanisms of amphetamines, such as MDMA, that
seem to involve mitochondrial impairment and metabolic
bioactivation of the drugs and intracellular Ca2+ homeostasis,
which can, in turn, abnormally alter myocardial excitability and
contractility (Tiangco et al., 2005; Carvalho et al., 2012).
Notwithstanding, in the corresponding drug scene, piperazines
have the reputation of being safe, and there are presently no
studies regarding their toxicity at the cellular level that could help
understanding the aforementioned detrimental effects of these
drugs. The aim of this work was to study the in vitro cardiotoxicity
of the piperazine designer drugs BZP, TFMPP, MeOPP, and MDBP
using the H9c2 cardiac cell line. The H9c2 is a cell line derived from
rat heart (Kimes and Brandt, 1976), that is considered a valuable
model to assess in vitro cardiotoxicity, especially because these
cells biochemical and electrophysiological properties are compa-
rable to those of adult cardiomyocytes and adequately mimic the
metabolic capacity of the rat heart (Zordoky and El-Kadi, 2007).
2. Material and methods
2.1. Chemicals
N-Benzylpiperazine (BZP, 99.3% purity) was purchased from
Chemos GmbH (Regenstauf, Germany), 1-(3-triﬂuoromethyl-
phenyl) piperazine (TFMPP, 98% purity) was acquired from Alfa
Aesar (Karlsruhe, Germany), 1-(4-methoxyphenyl) piperazine
(MeOPP, 96% purity) was purchased from Acros Organics (New
Jersey, USA), and 1-(3,4-methylenedioxybenzyl) piperazine
(MDBP, 97% purity) was purchased from Aldrich Chemistry
(Steinheim, Germany). Fetal bovine serum (FBS), trypsin (0.25%)–
EDTA (1 mM), and antibiotic (10,000 U/mL penicillin, 10,000 mg/
mL streptomycin), Hanks balanced salt solution (HBSS), and
phosphate buffer (PBS) were obtained from Gibco Laboratories
(Lenexa, KS, USA). Dulbecco's modiﬁed eagle's medium (DMEM)
with 4500 mg/L glucose, dichlorodihydroﬂuorescein diacetate
(DCFH-DA), tetramethylrhodamine ethyl ester perchlorate(TMRE), reduced glutathione (GSH), oxidized glutathione (GSSG),
glutathione reductase (GR, EC 1.6.4.2), 2-vinylpyridine, reduced
b-nicotinamide adenine dinucleotide (b-NADH), 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 5,5-
dithio-bis(2-nitrobenzoic) acid (DTNB), N-acetyl-Asp-Glu-Val-
Asp-p-nitroaniline (Ac-DEVD-pNA), 4-(2-hydroxyethyl) pipera-
zine-1-ethanesulfonic acid (HEPES), 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate hydrate (CHAPS), dithio-
threitol (DTT), ethylenediaminetetraacetic acid (EDTA), luciferin,
luciferase, campthotecin, and cyclosporine A were obtained from
Sigma–Aldrich (St. Louis, USA). Fluo-3 AM was obtained from
Molecular Probes (Eugene, OR). Dimethylsulfoxide (DMSO),
perchloric acid (HClO4), sodium phosphate dibasic (Na2HPO4),
sodium phosphate monobasic (NaH2PO4), potassium bicarbonate
(KHCO3), hydrogen peroxide (H2O2), sodium chloride (NaCl), and
glycerol were obtained from Merck (Darmstadt, Germany). Flow
cytometry reagents (BD Facs-FlowTM and Facs-CleanTM) were
purchased from BD (Becton, Dickinson and Company, San Jose,
CA, USA).
2.2. H9c2 cell culture
The H9c2 cell line was a generous gift from Dr. Vilma Sardão,
Center for Neurosciences and Cellular Biology, University of
Coimbra, Portugal. The cells were cultured in DMEM supplemented
with 10% FBS, 100 U/mL of penicillin, and 100 mg/mL of strepto-
mycin in 75 cm2 tissue culture ﬂasks at 37 C in a humidiﬁed 5%
CO2–95% air atmosphere. The cells were fed every 2–3 days, and
sub-cultured once 70–80% conﬂuence was reached.
2.3. Cytotoxicity assay
For the evaluation of cytotoxicity, the MTT reduction assay was
performed as previously described (Rossato et al., 2013). This assay
measures dehydrogenase activity, an indicator of metabolically
active mitochondria, and therefore, of cell viability. Cells were
seeded at a density of 35,000 cells/mL in 48-well plates (ﬁnal
volume of 250 mL; 8000 cells/cm2). Stock solutions of BZP were
made up in PBS. Stock solutions of TFMPP, MeOPP, and MDBP were
made in DMSO. In these cases, 0.1% DMSO in culture medium was
used as negative control. All stock solutions were stored at 20 C
and freshly diluted on the day of the experiment. Concentration–
response curves were obtained incubating the cells with 0–20 mM
of BZP, TFMPP, MeOPP, or MDBP for 24 h at 37 C. Triton X-100 1%
was used as positive control. After the incubation period, the
medium was removed and replaced with fresh medium containing
0.5 mg/L MTT. The cells were incubated at 37 C for 4 h. After
incubation, the cell culture medium was removed, and the formed
formazan crystals dissolved in DMSO. The absorbance was
measured at 550 nm in a multi-well plate reader (BioTek Instru-
ments, Vermont, USA). To reduce inter-experimental variability,
data were normalized and scaled between 0% (negative controls)
and 100% effect (positive controls). Results were graphically
presented as percentage of cell death vs concentration (mM). All
drugs were tested in three independent experiments with each
concentration tested in six replicates within each experiment.
2.4. Neutral red (NR) uptake assay
To conﬁrm the results obtained with the MTT reduction assay,
we performed the NR uptake assay. This assay is based on the
ability of viable cells to incorporate and bind the weak cationic dye
NR, which penetrates into the cells by non-ionic diffusion,
accumulating in lysossomes by interaction with anionic sites in
the lysosomal matrix (Labonne et al., 2009). At the end of 24 h
incubations of H9c2 cells with 0–20 mM of BZP, TFMPP, MeOPP, or
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50 mg/mL NR. The cells were incubated at 37 C in a humidiﬁed, 5%
CO2–95% air atmosphere for 3 h allowing the lysosomes of viable
cells to take up the dye. Thereafter, the cells were carefully washed
with 200 mL of HBSS to eliminate extracellular dye and lysed with a
50% ethanol–1% glacial acid acetic solution. Triton X-100 1% was
used as positive control. The absorbance was measured at 540 nm
in a multi-well plate reader (BioTek Instruments, Vermont, USA).
The percent cell death relative to that of the control cells was used
as the cytotoxicity measure.
2.5. Intracellular ROS and RNS production
The intracellular reactive oxygen (ROS) and nitrogen (RNS)
species productionwasmonitoredby means of the DCFH-DA assayas
previouslydescribed (Dias da Silva et al., 2013b). The sensitive DCFH-
DA lipophilic probe readily penetrates the cells producing 20,70-
dichlorodihydroﬂuorescein (DCFH) after hydrolysis, which further
reacts with intracellular ROS and RNS, including the hydroxyl radical
and hydrogen peroxide, generating green ﬂuorescent 20,70-dichloro-
ﬂuorescein (DCF), which is polar and trapped within the cells (Rao
et al., 1992; Smith and Weidemann, 1993). For this determination,
cells were seeded at a density of 35,000 cells/mL in 48-well plates
(ﬁnal volume of 250 mL, 8000 cells/cm2) and allowed to grow for
48 h. On the day of the experiment, the cells were pre-incubated with
10 mM DCFH-DA for 30 min, at 37 C, in the dark. As DCFH-DA is a
non-water-soluble powder, it was initially prepared as a 4 mM stock
solution in DMSO and made up to the ﬁnal concentration in fresh
culture medium (ensuring that the ﬁnal concentration of DMSO did
not exceed 0.05%) immediately before each experiment. The cells
were then rinsed with HBSS and incubated with the piperazine
designer drugs (1000 and 2000 mM BZP, MeOPP, or MDBP or 50 and
500 mM for TFMPP) at 37 C. H2O2 (150 mM) was used as a positive
control. Fluorescence was recorded on a ﬂuorescence microplate
reader (BioTek Instruments, Vermont, USA) set to 485 nm excitation
and 530 nm emission at times 0, 1, 2, 3, 4, 5, 6, 7, 8, and 24 h after
incubation. The data obtained were normalized to negative controls
on a plate-by-plate basis and calculated as fold increase over control
conditions from three independent experiments with each concen-
tration tested in three replicates within each experiment.
2.6. Measurement of intracellular total glutathione (tGSH), GSH, and
GSSG levels
Cells were seeded at a density of 35,000 cells/mL in 55 cm2
Petri dishes (ﬁnal volume of 12.5 mL, 8000 cell/cm2) and grown
for 48 h. The medium was then replaced and cells were incubated
at 37 C with the piperazine designer drugs (1000 and 2000 mM
BZP, MeOPP, or MDBP or 50 and 500 mM for TFMPP). After a 24 h
incubation period, the medium was removed, and the cells were
kept on ice while being scraped in PBS, pH 7.4. After centrifuga-
tion (210  g, 5 min, 4 C), the supernatant was removed. The pellet
of cells was lysed with 5% HClO4 and centrifuged (16,000  g,
10 min, 4 C). The obtained supernatant was frozen at 20 C until
further determination of tGSH and GSSG levels, evaluated by the
DTNB–GSSG reductase recycling assay, as previously described
(Rossato et al., 2013). Brieﬂy, the acidic supernatant was
neutralized with an equal volume of 0.76 M KHCO3 and
centrifuged (16,000  g, 2 min, 4 C). Total glutathione was
determined by transfering, in triplicate, 100 mL of the neutralized
supernatants, standards or blank (5% HClO4, w/v) to a 96-well
plate, followed by the addition of 65 mL of freshly prepared reagent
containing 0.24 mM NADPH and 0.7 mM DTNB in phosphate buffer
(71.5 mM Na2HPO4, 71.5 mM NaH2PO4, and 0.63 mM EDTA; pH 7.5).
The plates were then incubated for 15 min, at 30 C, in a microplate
reader (BioTek Instruments, Vermont, USA), prior to the addition of40 mL per well of a freshly prepared 10 U/mL glutathione reductase
solution in phosphate buffer. The stoichiometric formation of 5-
thio-2-nitrobenzoic acid (TNB) was followed every 10 s for 3 min at
415 nm at 30 C, and compared with a standard curve performed
for all readings. For the determination of GSSG, 10 mL of 2-
vinylpyridine was added to 200 mL aliquots of the acidic super-
natants and mixed continuously for 1 h at 0 C for derivatization of
the sulfhydryl groups (SH). GSSG was then measured as described
for tGSH. The GSH content was calculated by subtracting the GSSG
from the tGSH values [GSH = tGSH  (2  GSSG)]. The ﬁnal results
were expressed as percentage of control conditions from ﬁve
independent experiments with each concentration tested in three
replicates within each experiment.
2.7. Inﬂuence of piperazine designer drugs on glutathione reductase
(GR) activity
The activity of GR was evaluated by following the oxidation of
NADPH consumed during the reduction of GSSG at 340 nm, at a
constant temperature of 30 C (Remião et al., 2000). The enzyme
activity was determined by transferring 170 mL of a reaction
mixture containing 1 mM GSSG, 71.5 mM Na2HPO4, 71.5 mM
NaH2PO4, and 0.63 mM EDTA; pH 7.5, to which 50 mL of a freshly
prepared 0.5 U/mL glutathione reductase solution in phosphate
buffer and 100, 500, 1000, and 2000 mM BZP, MeOPP, or MDBP or 5,
50, 100, and 500 mM TFMPP were added. After 2 min pre-
incubation, the reaction was initiated by the addition of 30 mL
1 mM NAPH in phosphate buffer. The kinectics of the reaction was
monitored for 5 min at 20 s intervals. A blank assay containing all
components of the reaction mixture except the enzyme was
performed to evaluate the non-enzymatic oxidation of NADPH,
which was subtracted from the assay values. As a positive control,
DHBA (3,4-dihydroxybenzylamine) was used. The ﬁnal results
were expressed as percentage of control conditions from three
independent experiments with each concentration tested in three
replicates within each experiment.
2.8. Measurement of intracellular ATP levels
Cells were seeded, treated and incubated following the same
protocol used for the measurement of glutathione levels. After
centrifugation (210  g, 5 min, 4 C), the supernatant was removed.
The pellet of cells was lysed with 5% HClO4, centrifuged (16,000  g,
10 min, 4 C), and the supernatant obtained was frozen at 20 C
until further determination of the ATP intracellular content. The
ATP levels were quantiﬁed by a bioluminescence assay, as
described by Rossato et al. (2013). Brieﬂy, the acidic supernatant
was neutralized with an equal volume of 0.76 M KHCO3 and
centrifuged (16,000  g, 1 min, 4 C). The ATP contents were then
measured in duplicate in 96-well white plates, by adding 100 mL of
the neutralized supernatants, standards or blank (5% HClO4, w/v)
and 100 mL of the luciferin/luciferase solution [0.15 mM luciferin,
300,000 light units of luciferase from Photinus pyralis (American
ﬁreﬂy), 50 mM glycine, 10 mM MgSO4, 1 mM Tris, 0.55 mM EDTA,
1% BSA (pH 7.6)]. The emitted light intensity was determined using
a luminescence microplate reader (BioTek Instruments, Vermont,
USA) and compared with a standard curve performed within each
experiment. The ﬁnal results were expressed as percentage of
control conditions from ﬁve independent experiments with each
concentration tested in two replicates within each experiment.
2.9. Flow cytometry analysis of intracellular Ca2+ levels
Intracellular Ca2+ levels were evaluated with the sensitive
ﬂuorochrome Fluo3-AM. After uptake by live cells, Fluo3-AM is
enzymatically hydrolyzed by intracellular esterases to Fluo3,
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intensity. A protocol previously described (Rossato et al., 2013)
was used with minor modiﬁcations. Cells were seeded at a
density of 35,000 cells/mL in six-well plates (ﬁnal volume of
2.5 mL, 9,000 cells/cm2). After 48 h, the medium was replaced
by fresh medium containing 500 and 1000 mM BZP or MDBP, or
250 and 500 mM MeOPP, or 10, 50, and 100 mM TFMPP. Twenty-
four hours after exposure, the cells were harvested by
trypsinization (0.05% trypsin/EDTA), centrifuged (300  g,
5 min, 4 C), and then loaded with 10 mM Fluo3-AM in 50 mL of
heated serum-free DMEM without phenol red, for 30 min, at
37 C, in a water bath with shaking. After this incubation period,
the cells were centrifuged (300  g, 5 min, 4 C) washed by
resuspending in 500 mL of heated HBSS (with Ca2+ and Mg2+),
centrifuged again (300  g, 5 min, 4 C), and kept on ice until ﬂow
cytometry analysis.
Sample analysis was performed in a FACSCaliburTM ﬂow
cytometer (BD, CA, USA), equipped with a 488 nm argon ion laser,
using CellQuest software (BD Biosciences). The green ﬂuores-
cence of Fluo3 was measured by a 530  15 nm band-pass ﬁlter
(FL1). After resuspending the cell pellet in HBSS (+/+) with 0.5 mg/
mL propidium iodide (PI) (after permeating death cells, PI
interlaces with the nucleic acid helix with consequent increase
in ﬂuorescence intensity emission at 615 nm), data from at least
15,000 viable cells (based on their forward and side light scatter)
were collected from each test condition. In order to detect a
possible contribution from cells auto-ﬂuorescence to the ana-
lyzed ﬂuorescence signals, portions of cell suspension (with or
without exposure to the drugs), which were not incubated with
Fluo3-AM, were analyzed in the 530  15 nm band-pass ﬁlter
(FL1). Results are presented as Fluo3 ﬂuorescence intensity
(percentage of control) from at least six independent experiments
with each concentration tested in two replicates within each
experiment.
2.10. Assesment of mitochondrial membrane potential (Dcm)
Assessment of mitochondrial integrity was performed by
measuring TMRE inclusion as described by Dias da Silva et al.
(2013c). TMRE is a cell permeable ﬂuorescent dye that
speciﬁcally stains live mitochondria, and accumulates in
proportion to the mitochondrial membrane potential (Dcm)
(Scaduto and Grotyohann, 1999). Cells were seeded at a density
of 35,000 cells/mL in 48-well plates (ﬁnal volume of 250 mL;
8000 cells/cm2). After 48 h, the medium was gently aspirated,
and the cells were incubated with the piperazine designer drugs
(500, 1000, and 2000 mM for BZP, MeOPP, or MDBP or 10, 50,
100, 500, and 1000 mM for TFMPP). At the end of the 24 h
incubation period, the medium was replaced by fresh medium
containing 2 mM TMRE, and incubated at 37 C, for 30 min, in
the dark. As TMRE is a non water-soluble powder, a 2 mM stock
solution was initially prepared in DMSO and stored in the dark.
Afterwards, the medium was gently aspirated and replaced by
0.2% BSA in HBSS. Fluorescence was measured on a ﬂuorescence
microplate reader (BioTek Instruments, Vermont, USA) set to
544 nm excitation and 590 nm emission. The data obtained
were normalized on a plate-by-plate basis to the values of the
respective controls and calculated as the percentage of control
conditions from at least six independent experiments with each
concentration tested in three replicates within each experiment.
Although rhodamines can undergo self-quenching at high
concentrations (up to 150 nM), the use of low concentrations
may cause a loss of sensibility in detecting small Dcm
depolarizations. The 2 mM TMRE tested concentration has been
successful in detecting Dcm alterations in previous works (Dias
da Silva et al., 2013c).2.11. Inhibition of the mitochondrial permeability transition pore
(MPTP)
The mitochondrial permeability transition pore is sensitive to
cyclosporin A (CsA) that blocks the opening of this pore. To
evaluate the role of MPTP in the cytotoxicity mediated by
piperazine designer drugs, H9c2 cells were seeded at a density
of 35,000 cells/mL in 48-well plates (ﬁnal volume of 250 mL;
8000 cells/cm2). After 48 h cells were pre-treated for 30 min, and
co-incubated with 1 mM CsA to inhibit the MPTP. After the pre-
incubation, cells were incubated with 500, 1000, 1500, and
2000 mM BZP, MeOPP, or MDBP or 50, 100, 250, and 500 mM
TFMPP. After 24 h, cell mortality was determined through the MTT
reduction assay. The ﬁnal results were expressed as percentage of
control conditions from four independent experiments with each
concentration tested in three replicates within each experiment.
2.12. Cell death mode: apoptosis vs necrosis
Cell death analysis was performed by staining H9c2 cells with
Annexin V-FITC and propidium iodide (PI) (FITC Annexin V
Apoptosis Detection Kit BD Biosciences, USA). Annexin V binds
to exposed phosphatidylserine on the plasma membrane of the
early apoptotic cells, while late apoptotic and/or necrotic cells are
stained by PI. To perform the assay, H9c2 cells were seeded at a
density of 12,000 cells/mL in 48-well plates (ﬁnal volume of
250 mL; 3,000 cells/cm2). After 48 h, the cells were incubated
with 360 mM BZP, 70 mM TFMPP, 380 mM MeOPP, and 500 mM
MDBP. After the 24 h incubation period, the medium was removed,
and 100 mL binding buffer was added, followed by 2 mL PI and 3 mL
annexin V-FITC. Plates were incubated in the dark at room
temperature. After 15 min, the cells were observed under a
ﬂuorescence microscope (Nikon, Tokyo, Japan). Five pictures per
well were taken, and the percentages of early apoptotic cells were
estimated by counting the annexin V-positive but PI-negative cells,
whereas the percentages of late apoptotic cells were estimated by
counting the number of cells which were both annexin V-positive
and PI-positive. Necrotic cells were the PI-positive but annexin V-
negative ones. Campthotecin 12 mM was used as a positive control
for apoptosis. The results are expressed as percentage cell
population from 4 independent experiments.
2.13. Caspase-3 activity assay
Cells were seeded at a density of 35,000 cells/mL in six-well
plates (ﬁnal volume of 2.5 mL, 9000 cells/cm2) and allowed to
grow. After 48 h, the medium was replaced, and cells were
incubated with piperazine designer drugs at 37 C (1000 and
2000 mM for BZP, MeOPP, or MDBP or 50 and 500 mM for TFMPP).
After a 24 h incubation period, the cells were detached and
collected to a tube (two wells per tube), centrifuged (210  g, 5 min,
4 C), and the supernatant was discarded. One hundred and ﬁfty
microliters of lysis buffer (50 mM HEPES, 0.1 mM EDTA, 0.1%
CHAPS, supplemented with 1 mM DTT, pH 7.4) were added to the
pellets, votex-mixed and incubated on ice for 5 min before
centrifugation (16,000  g, 10 min, 4 C). In a 96-well plate,
50 mL of the supernatant, which contains the cytoplasmic fraction,
was mixed with 200 mL of assay buffer (100 mM NaCl, 50 mM
HEPES, 1 mM EDTA, 0.1% CHAPS, 10% glycerol, supplemented with
10 mM DTT, pH 7.4). The reaction was started by adding 5 mL of
caspase-3 peptide substrate Ac-DEVD-pNA (ﬁnal concentration
80 mM) and subsequent incubation at 37 C for 24 h. Caspase-3
releases the p-nitroaniline moiety of the substrate, which presents
high absorbance at 405 nm. All steps were performed on ice, and
the caspase-3 activity was determined at 405 nm in a multi-well
plate reader (BioTech Instruments, Vermont, US) as previously
Fig. 2. Concentration–response (cell death) curves of the tested piperazine
designer drugs after 24 h incubation in H9c2 cells at 37 C. Cell viability was
evaluated by the MTT reduction (A) and the neutral red uptake (B) assays. Data are
presented as percentage of cell death relative to the respective negative controls.
Three independent experiments were performed (six replicates tested for each
concentration within each experiment). Curves were ﬁtted using least squares as
the ﬁtting method.
Table 1
EC50 values of the piperazine designer drugs.
Designer drug EC50 MTT EC50 NR
(mM) (mM)
BZP 343.9 2332b
TFMPP 59.6a 186.4a,c,d
MeOPP 570.1a,b 2366b
MDBP 702.5a,b 2469b
The cytotoxicity curves were ﬁtted using least squares as the ﬁtting method.
Comparisons were made using the extra sum-of-squares F test (p < 0.05).
a Compares to BZP.
b Compares to TFMPP.
c Compares to MeOPP.
d Compares to MDBP.
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(stock solution at 4 mM) and DTT were prepared in DMSO. The
absorbance of blanks, used as non-enzymatic control, was
subtracted from each value of absorbance. Final results of
caspase-3 activity were expressed as optical density at 405 nm/
mg of protein. The protein content in the cytoplasmic fraction was
quantiﬁed using the Bio-Rad DC protein assay kit as described by
the manufacturer, and bovine albumin solutions were used as
standards. Campthotecin (12 mM) was used as positive control.
2.14. Statistical analysis
Concentration–response curves were obtained from six repli-
cates of each tested concentration from three independent experi-
ments. They were ﬁtted by the least squares method. The
comparisons between curves (bottom, top and log EC50) were made
using the extra sum-of-squares F test. Results of all other
biochemical measures are presented as mean  standard error of
the mean (SEM) from at least three independent experiments.
Normalityof the data distributionwas assessed by the Kolmogorov–
Smirnov normality test. Signiﬁcance was accepted at p < 0.05.
Statistical comparisons between groups were performed with one-
way ANOVA (when data followed normal distribution) or with the
Kruskal–Wallis test (one-way ANOVA on ranks in case data
distribution was not normal). A two-way ANOVA analysis was
conducted when the cells were submitted to a drug challenge after
pre-incubation with the MTPT opening inhibitor CsA. Details of the
statistical analysis are provided in the text and legend of the ﬁgures.
3. Results
3.1. Piperazine designer drugs elicit concentration-dependent
cytotoxicity in H9c2 cells
A comprehensive concentration–response analysis was carried
out by incubating the H9c2 cells with 0–20 mM of each piperazine
designer drug for 24 h. Fig. 2 presents the obtained concentration–
response curves showing that in the MTT (A) and NR (B) assays, all
tested drugs produced concentration-dependent cytotoxic effects.
A summary of the calculated EC50 values (representing the half-
maximum-effect concentrations from the ﬁtted curves) is pre-
sented in Table 1. Signiﬁcant differences were observed for the EC50
values of the curves. Based on these data, it was evident that, under
our experimental conditions, TFMPP (EC50 59.6 mM) was the most
cytotoxic of the tested piperazine designer drugs to H9c2 cells,
followed by BZP (EC50 343.9 mM), MeOPP (EC50 570.1 mM), and
MDBP (EC50 702.5 mM). To conﬁrm these results, we also
performed the NR uptake assay. The EC50 values were higher
than those obtained with the MTT assay, but the cytotoxicity
proﬁle of the piperazine designer drugs was the same (Table 1,
Fig. 2B).
3.2. Oxidative stress does not contribute to the cytotoxic effects elicited
by the piperazine designer drugs
Oxidative stress plays an important role in drug-induced
cardiotoxicity for many different compounds including drugs of
abuse (e.g., cocaine and amphetamines), and pharmaceuticals (e.g.,
doxorubicin and cyclophosphamide) (Costa et al., 2013). The effect
of piperazine designer drugs in the generation of reactive species
was, therefore, evaluated by the DCFH-DA assay at different time-
points, but no signiﬁcant changes in reactive species generation
were found for any of the tested piperazine drugs even when tested
at highly cytotoxic concentrations (data not shown).
Changes in the intracellular amounts of GSH and GSSG are also
strong indicators of redox disturbances and were investigated withthe DTNB–GSSG reductase recycling assay. In accordance with the
data from the DCFH-DA assay, the intracellular GSH levels were not
depleted by the piperazine test drugs, even at highly cytotoxic
concentrations, with the exception of MDBP. As can be seen in
Fig. 3, total GSH levels were signiﬁcantly decreased (p < 0.05,
ANOVA/Bonferroni) after 24 h incubations with 1000 and 2000 mM
MDBP as compared to control (representing a 23% and 37%
decrease, respectively). GSSG was also detected in H9c2 cells:
however, no changes in the intracellular levels of the dissulﬁde
were observed for any of the tested drugs (data not shown). Thus,
the observed depletions in total GSH levels are probably due to a
decrease in reduced GSH intracellular levels as a consequence of
Fig. 3. (A) Intracellular contents of total glutathione (tGSH) in H9c2 cells after 24 h
incubations with the tested piperazine designer drugs at 37 C. (B) Effect of
piperazine designer drugs in the activity of GSH reductase (GR). Results are
expressed as percentage control  SEM (n = 5 independent experiments run in
triplicates). Statistical comparisons were made using one-way ANOVA/Bonferroni
post-hoc test (*p < 0.05; ***p < 0.001 vs control).
Fig. 4. Intracellular contents of ATP in H9c2 cells after 24 h incubations with the
tested piperazine designer drugs at 37 C. Results are expressed as percentage
control  SEM (n = 5 independent experiments run in duplicates). Statistical
comparisons were made using one-way ANOVA/Bonferroni post-hoc test (*p
< 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 vs control).
Fig. 5. Intracellular levels of Ca2+ in H9c2 cells after 24 h incubations with the tested
piperazine designer drugs at 37 C. Results are expressed as percentage control 
SEM (n = 6 independent experiments run in duplicates). Statistical comparisons
were made using the non-parametric Kruskal–Wallis test (*p < 0.05; ***p < 0.001;
****p < 0.0001 vs control).
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can conjugate GSH but an interference with the enzymes involved
in GSH homeostasis, namely with glutathione reductase (GR),
cannot be discarded. To test this hypothesis, the inﬂuence of the
piperazine designer drugs on the activity of the GR enzyme was
measured, and no differences were found at the concentration
range tested (Fig. 3B).
3.3. Piperazine designer drugs disturb the cellular energetic status and
Ca2+ homeostasis
ATP, the key intermediate for energy exchange, is engaged in a
variety of cellular activities, including cellular energetics, meta-
bolic regulation, and signalling. Since all cells require ATP to
remain alive and carry out their speciﬁc functions and, because ATP
is transiently depressed by many forms of cellular stress, its levels
reﬂect the functional integrity of viable cells. Fig. 4 shows that the
ATP levels measured in H9c2 cells after 24 h incubations with the
tested piperazine designer drugs at 37 C were signiﬁcantly
depleted at highly cytotoxic concentrations. Signiﬁcant (p < 0.05,
ANOVA/Bonferroni) 23 and 45% decreases in ATP levels in relation
to negative controls were observed at 1000 and 2000 mM BZP. For
500 mM TFMPP, a 45% decrease was noted, while this decrease was
of 28% for 2000 mM MeOPP, and 27% and 35%, respectively, for 1000
and 2000 mM MDBP.
Intracellular Ca2+ homeostasis is also critical for maintaining
the normal function of the cell, in that variations in theconcentration of Ca2+ in cells can determine cell survival or
death (Oliveira and Gonçalves, 2009). Incubation with pipera-
zine designer drugs signiﬁcantly increased (p < 0.05, Kruskal–
Wallis) the intracelular Ca2+ levels in a concentration-dependent
manner. As shown in Fig. 5, a 37% increase occured at 1000 mM
BZP in relation to negative controls. At 50 and 100 mM TFMPP,
mean ﬂuorescence markedly increased up to 89% and 123% over
control values, respectively. At 500 mM MeOPP and 1000 mM
MDBP increases of 130% and 118% relative to control, respec-
tively, could also be observed.
Fig. 6. Mitochondrial membrane potential (Dcm) measured as TMRE incorpo-
ration in mitochondria of H9c2 cells after 24 h incubations with the tested
piperazine designer drugs at 37 C. Results are expressed as percentage control 
SEM (n = 6 independent experiments run in triplicates). Statistical comparisons
were made using one-way ANOVA/Bonferroni post-hoc test (**p < 0.01; ***p
< 0.001 vs control).
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designer drugs
To investigate whether the piperazine drugs could disturb the
mitochondrial function, the mitochondrial membrane potential
(Dcm) was evaluated. A signiﬁcant loss of Dcm impairs oxidative
phosphorylation, depleting cells of energy, and inducing cell death.
In Fig. 6, a signiﬁcant loss in Dcm (p < 0.01, ANOVA/Bonferroni)Fig. 7. Involvement of the mitochondrial permeability transition pore (MPTP) in the p
reduction assay in H9c2 cells after 24 h incubations with the tested piperazine designer d
cyclosporine A (CsA) at 37 C. Results are expressed as percentage control  SEM (n = 4 in
two-way ANOVA/Bonferroni post-hoc test, for comparisons vs the respective control cond
same concentration with or without 1 mM CsA (#p < 0.05; ##p < 0.01 vs incubation wican be observed after 24 h incubations of H9c2 cells with 100, 500,
and 1000 mM TFMPP (with decreases of 18, 43 and 39%,
respectively) in relation to control values. At 500, 1000, and
2000 mM MeOPP, this loss comprises 21, 33, and 35% of control
Dcm, while 27, 33, and 36% decreases in Dcm relative to control
occurred at 500, 1000, and 2000 mM MDBP, respectively. BZP did
not produce any measurable modiﬁcations in Dcm even at highly
cytotoxic concentrations.
Increase of intracellular Ca2+ levels, loss of Dcm, and ATP
depletion are indicative signals of MPTP opening. Fig. 7 shows the
involvement of MPTP in the cytotoxic effects of the tested
piperazine designer drugs. When the H9c2 cells were incubated
with the tested drugs in the presence of 1 mM cyclosporine A (CsA)
(including a pre-incubation period of 30 min), it was possible to
observe a partial reversion of the piperazine designer drugs
cytotoxic effects. In fact, the cytotoxic effects produced by 1500
and 2000 mM BZP after pre-incubation with 1 mM CsA were
signiﬁcantly lower (p < 0.05, ANOVA/Bonferroni) than those
observed in the absence of CsA. In these set of experiments, the
BZP control incubations without CsA revealed lower toxicity levels
than those expected from the cytotoxicity curves, but this is likely
explained by the steepness of the MTT cytotoxicity assay curve at
these concentration ranges. The cells incubated with 50, 100, 250,
and 500 mM TFMPP presented a signiﬁcant (p < 0.001, ANOVA/
Bonferroni) cytotoxic effect in the MTT assay. The incubation with
CsA 1 mM was capable to slightly but signiﬁcantly increase cell
survival at the tested 50 and 100 mM TFMPP concentrations.
However, the protective effects of CsA were not observed for the
higher and more cytotoxic TFMPP concentrations. Incubation with
MeOPP also resulted in a signiﬁcant (p < 0.001, ANOVA/Bonferroni)
cell death. CsA was able to signiﬁcantly (p < 0.05, ANOVA/
Bonferroni) increase cell survival only at 2000 mM MeOPP. Theiperazine designer drugs-induced cell death. Viability was evaluated by the MTT
rugs with and without 30 min pre-incubation followed by co-incubation with 1 mM
dependent experiments run in triplicates). Statistical comparisons were made using
ition (*p < 0.05; **p < 0.01; ***p < 0.001 vs control) and for comparison between the
thout 1 mM CsA).
Fig. 8. Annexin V/PI staining of H9c2 cells after 24 h incubations with the tested
piperazine designer drugs at 37 C. The H9c2 cell population was divided into early
apoptotic (annexin V+/PI), late apoptotic (annexin V+/PI+), and necrotic (annexin
V/PI+) cells. Results are expressed as percentage cell population  SEM (n = 4
independent experiments). Statistical comparisons were made using one-way
ANOVA/Bonferroni post-hoc test (*p < 0.05; **p < 0.01; ***p < 0.001 vs control).
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after MDBP incubations but only at the highest 2000 mM tested
concentration of the drug. In spite of the observed increases in
survival, cell viability after CsA incubations was still signiﬁcantly
lower than control (p < 0.05, ANOVA/Bonferroni).
In order to evaluate the mode of death, the cells were stained
with annexin V-FITC and PI after 24 h incubations with the
piperazine designer drugs at concentrations that approximately
corresponded to their EC50 levels, as determined by the MTT assay.
Fig. 8 depicts the relative number (percentage of cell population) of
early apoptotic, late apoptotic (undergoing secondary necrosis)
and necrotic H9c2 cells. At the tested concentrations, after
incubation with all piperazine test drugs a high number of cells
presenting early apoptosis features, i.e., stained only with annexin
V-FITC could be observed relative to the control cell population
(Fig. S1, Supplemented material). A high number of cells that were
double-stained with both annexin V-FITC and PI were also found
after the drug incubations. These cells are likely undergoing
secondary necrosis and present features of both types of cell death.
The number of necrotic cells did not signiﬁcantly differ from
control cells for any of the piperazine designer drugs.
Supplementry material related to this article found, in the
online version, at http://dx.doi.org/10.1016/j.toxlet.2014.06.031.
Notwithstanding, when the activation of caspase-3, that is
involved in the apoptotic cascade, was investigated, no signiﬁcant
changes in this downstream effector caspase activity were
observed after 24 h incubations (data not shown).
4. Discussion
A recent survey in the UK found that piperazines are among the
most common active recreational drugs in tablets purchased from
internet supplier sites (Davies et al., 2010). These so-called party
pills gained popularity in the 2000s as a legal and arguably safer
alternative to MDMA. However, the available information on the
toxic effects of piperazine designer drugs is currently very limited.
For the ﬁrst time, we demonstrate that piperazine designer
drugs produce cytotoxicity to H9c2 cells, a commercially available
myogenic cell line derived from embryonic rat heart ventricle that
has been considered suitable for the study of drug-induced
cardiotoxicity (Watkins et al., 2011), specially due to their
metabolic competence that parallels the metabolic capacity of
the heart (Zordoky and El-Kadi, 2007). Among the four testedpiperazine designer drugs, TFMPP was the most potent drug to
elicit cytotoxic effects. This is in accordance with the cardiovascu-
lar effects experienced by users (Wood et al., 2008; Kovaleva et al.,
2008; Gee et al., 2010). In this work, we used two viability tests, the
MTT reduction and the NR uptake assays, to determine the
cytotoxicity of the piperazine designer drugs. In spite of the
differences in the obtained EC50 values, the cytotoxicity proﬁle of
the drugs was the same for the two tests. Discrepancies among
different viability tests are quite commonly noted in the literature
(Putnam et al., 2002; Weyermann et al., 2005; Pohjala et al., 2007;
Kim et al., 2009; Zwolak, 2013). The main difference between
these two assays is that MTT measures the activity of succinate
dehydrogenase, which is present in the mitochondrial inner
membrane (Putnam et al., 2002), while NR is based on the storage
of NR dye in the lysosomes and probably in the golgi apparatus
(Zwolak, 2013). Any damage to lysosomes/golgi apparatus
decreases the cellular accumulation of the dye. On the other
hand, mitochondrial succinate dehydrogenase is sensitive to local
changes in ion concentrations and ion ﬂux. It is not uncommon for
some chemicals to increase metabolic activity in a cell, which
would result in increased mitochondrial succinate dehydrogenase
activity (Putnam et al., 2002). Also, MTT does not seem to be
appropriate for the evaluation of cytotoxicity in cells with an
unchanged reduction ﬂuctuation by a high level of basal cellular
reduction capacity and/or oxidant defense (Kim et al., 2009). In the
present case, oxidative stress does not seem to contribute to the
toxic effect of piperazine designer drugs in H9c2 cells, and the
piperazine derivatives alter ionic concentration through the
disruption of Ca2+ homeostasis. Therefore, MTT is probably not
the best test for evaluation the cytotoxicity of the piperazine
designer drugs. Accordingly, the NR cytotoxicty data agree much
better with the oxidative stress and energetic imbalance endpoints
additionally measured, while the MTT seems to overestimate the
cytotoxic potential of the piperazine designer drugs.
Oxidative stress is a well-described mechanism underlying the
toxicity of many xenobiotics, which plays an essential role in the
cytotoxic effects of several amphetamine derivatives that induce
the formation of highly reactive species (Dias da Silva et al., 2013b).
Interestingly, piperazine designer drugs failed to induce reactive
species formation, as measured through the DCFH-DA assay. GSH
has an important protective role which involves its oxidant
neutralizing and lipid peroxidase and/or tocopheryl radical-
regenerating activities. Changes in the intracellular amounts of
GSH and GSSG are, therefore, strong indicators of redox
disturbances. In agreement with the DCFH-DA assay data, the
intracellular GSH level remained signiﬁcantly unchanged upon
incubation with the piperazine designer drugs with the exception
of MBDP. Our data indicate a decrease in intracelular tGSH content
after incubation with MDBP for 24 h. However, these decreases
were not accompanied by signiﬁcant alterations in GSSG levels or
inhibition of the GR enzymatic activity. A possible explanation for
this result is that the GSSG formed through the free radicals
neutralizing reactions of GSH could be extruded for the extracel-
lular medium, contributing to the decrease in the tGSH levels. This
GSSG efﬂux is a cellular response that protects the cells from
oxidative stress (Rossato et al., 2011). However, since no formation
of reactive species could be observed, it is not likely that the
observed depletion in tGSH levels is due to increased GSSG
formation. Depletion may be caused by inhibition of GSH
biosynthesis (Gao et al., 2010), which occurs in the cytosol, and
involves two enzymes: g-glutamylcysteine ligase and GSH
synthase, the ﬁrst catalyzing the rate-limiting step of this
biosynthetic pathway (Marí et al., 2013). A key role in GSH
homeostasis is also played by g-glutamyl transpeptidase (GGT),
which breaks down extracellular GSH and provides cysteine, the
rate-limiting substrate, for intracellular de novo synthesis of GSH
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GSSG by GR producing two molecules of GSH. GR is known to be
sensitive to chemical modiﬁcation of its active thiol groups. Thus,
the activity of GR can be modulated by the redox conditions of the
reactive environment. Under extreme oxidising conditions, aggre-
gates of GR may be formed, which decrease GR activity (Remião
et al., 2000). However, according to our results, the piperazine
designer drugs do not seem to have any inﬂuence on the GR
activity.
In fact, it has been previously described that the cardiotoxicity
of MDMA involves the formation of catechol metabolites that are
oxidized into quinone intermediates following the demethylena-
tion of MDMA (Hiramatsu et al., 1990) and methylenedioxyam-
phetamine (MDA) (Carvalho et al., 2004) leading to the production
of the corresponding glutathione-S-yl-N-methyl-a-methyldop-
amine and glutathione-S-yl-a-methyldopamine conjugates. There
is a striking similarity with the main metabolic pathways that were
already described for MDBP in animals and in humans, namely the
demethylenation of MDBP (Staack and Maurer, 2004), which can
lead to the formation of similar GSH adducts, since a catechol
intermediate is also formed. Although such conjugate formation is
yet to be demonstrated, this possible metabolic bioactivation
affords an alternative and reasonable explanation for the GSH
decreases that were observed with only MDBP.
Cardiac myocytes are endowed with high content of mitochon-
dria, equivalent to approximately 30% of the cellular volume, and
maintain an elevated rate of ATP synthesis to satisfy the energy
demand of the heart (Lax et al., 2009). Depletion of ATP is a typical
feature of hypoxic and toxic injury and could be due to an
alteration in mitochondrial function. Indeed, mitochondria seems
to play an essential role in piperazine designer drugs-induced
cardiotoxicity. Mitochondria is generally considered the ‘power-
house’ of the cell in generating ATP, but they also play an important
role in other aspects of normal cell functioning. Apart from ATP
synthesis, mitochondrial Ca2+ uptake represents a major function
of mitochondria; thus, regulating Ca2+-dependent signalling
pathways (Grifﬁths, 2000). Ca2+ uptake is driven by the electro-
chemical potential gradient generated by the combination of the
Dcm and the low concentration of Ca2+ in the matrix (Duchen,
1999). It is well established that mitochondria accumulate Ca2+
ions during cytosolic Ca2+ elevations in a variety of cell types
including cardiomyocytes (Kumar et al., 2012). The downward
electrochemical gradient across the inner membrane directs Ca2+
into the mitochondria through an uniporter. If mitochondrial
buffering capacity is overwhelmed by elevated Ca2+, mitochondrial
matrix Ca2+ increases to levels high enough to trigger the opening
of the mitochondrial permeability transition pore (MPTP). This
involves the formation of pores in the inner membranes of pores
with 1.5 kDa, allowing the inﬂux of water and solutes into the
matrix. Although MPTP can ‘ﬂicker’ and be reversible, sustained
transitions lead to the collapse of Dcm, cessation of ATP
production, and cell death (Dong et al., 2006). Disruptions in
Ca2+ homeostasis may abnormally alter myocardial excitability and
contractility and induce arrhythmia or ventricular ﬁbrillation.
Increased intracellular Ca2+ may also affect signalling pathways,
leading to diverse responses including ﬁbrosis and hypertrophy
(Tiangco et al., 2005).
Our data show that piperazine designer drugs alter the Ca2+
homeostasis, leading to an increase in cytosolic free Ca2+ levels,
observed with 1000 mM BZP and MDBP, 500 mM MeOPP, and
50 mM TFMPP. At higher concentrations, the mitochondria
buffering capacity was overwhelmed and led to the loss of
Dcm and mitochondrial depolarization and the depletion of ATP.
In response to mitochondrial depolarization, the ATP synthase
reverts to an ATPase activity, consuming ATP and pumping
protons outwards, in a futile, energy consuming cycle (Duchen,1999). According to the chemiosmotic theory of mitochondrial
oxidative phosphorylation, Dcm is the driving force behind
oxidative phosphorylation. Thus, maintenance of Dcm is
extremely important for normal cell function (Mathur et al.,
2000). Generation of Dcm depends on a proton gradient across
the inner mitochondrial membrane. It is known that translocation
of protons from the matrix to the intermembrane space to
establish Dcm is coupled to the mitochondrial electron transport
chain (Yuan and Acosta, 1996). Inhibition of chain activity
undoubtedly diminishes Dcm, and this could be another pathway
through which piperazine designer drugs decrease cellular
energy and impair mitochondrial function. Using the same
H9c2 cellular model, other studies conducted with MDMA, a
drug which mimics the piperazine designer drugs effects,
similarly demonstrated the involvement of increased intracellular
Ca2+ concentrations and loss of Dcm in the cytotoxic effects of the
drug (Tiangco et al., 2005).
Since these results suggest the involvement of MPTP in these
cytotoxic events, we pre-incubated cells with CsA and then further
incubated the piperazines designer drugs in the presence of CsA.
Cyclosporin A binds to cyclophilin D, part of the MPTP, causing
inhibition of the MPTP opening and preventing cell death
(Crompton, 1999). The incubations with CsA only partially, but
signiﬁcantly, prevented cell death induced by the tested piperazine
drugs. It is plausible that the inhibition of MPTP open did not block
Ca2+ inﬂux and, therefore, did not prevent the alteration in the
electron gradient across the inner membrane. Also, Ca2+ may
possibly enter the matrix through alternative pathways other than
the Ca2+ uniporter. Recently, growing bodies of evidence of other
mechanisms related to the mitochondrial Ca2+ inﬂux have been
reported. These mechanisms involve the mitochondrial ryanodine
receptor, a rapid mode of Ca2+ uptake, mitochondrial uncoupling
proteins, and leucine zipper EF hand-containing transmembrane
protein 1 (LETM1) Ca2+/H+ antiporter. Ca2+ inﬂux through these
alternative Ca2+ uptake channels could also trigger MPTP opening
(Yarana et al., 2012).
MPTP opening generally represents a catastrophe for the cell
and will lead inexorably to cell death, either through ATP
consumption, acute energy failure and necrosis or through the
initiation of apoptosis (Duchen, 1999). Whereas the loss of ion
homeostasis resulting from ATP depletion can lead to necrosis,
MPTP opening also causes a leakage of cytochrome c from
mitochondria, and thus, triggers a cascade of events that
eventually lead to apoptosis (Chiu et al., 2008). Apoptotic cells
are characterized by a set of distinct morphological changes,
which can be classiﬁed as early and late apoptotic changes. The
early marker of apoptosis is the exposition of phosphatidilserine
on the cell surface (it is normally concentrated in the luminal
layer of the cytoplasmic membrane), while, at the later stage, the
entire phosphatidylserine is ﬂipped on the outer membrane
(Kumar et al., 2012). When the rate of apoptosis is substantially
increased, the cells undergo secondary necrosis (or late apopto-
sis) with breakdown of membrane potential, cell swelling and cell
contents release. These cells present features of both the
apoptotic and necrotic cells and in many cases can only be
accurately distinguished with detailed morphological analysis.
When the mode of cell death was investigated, we found an
unexpected high number of cells that were at an early apoptotic
stage and a low number of necrotic cells. However, an elevated
number of cells that were double-stained and most likely
undergoing secondary necrosis was also noted for all the
piperazine drugs; thus, agreeing with the previous data that
clearly indicated a preferential necrotic cell death pathway
characterized by the loss of Dcm, ATP depletion and MPTP
opening. Accordingly, under our experimental conditions, we did
not observe any activation of downstream effector caspase-3,
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However, alternative mechanisms for apoptosis induction that
are independent of caspases activation have been described. In
fact, activation of calpains due to increased intracellular Ca2+
concentrations has been linked to cardiomyocyte death. A
mechanism for ceramide-induced cardiomyocyte death with
apoptosis induction, which can turn into necrosis, following ATP
depletion, increased Ca2+ inﬂux, mitochondrial network frag-
mentation and loss of the mitochondrial Ca2+ buffer capacity
dependent on calpains activation and independent of caspases or
reactive species production has been described (Parra et al.,
2013). Nevertheless, the involvement of apoptotic and necrotic
pathways should be further investigated for a better comprehen-
sion of the cell death mechanisms involved in the cytotoxicity of
the piperazine designer drugs.
In conclusion, we describe, for the ﬁrst time, the cardiotoxic
effects of piperazine designer drugs in an in vitro model. Among
the tested designer drugs, TFMPP was the most potent in inducing
cytotoxicity. In H9c2 cells, piperazine designer drugs induced cell
death by causing disturbances in Ca2+ homeostasis, ATP depletion,
loss of Dcm and MPTP opening. It should be noted that these drugs
are frequently consumed in associations, such as TFMPP with BZP
or BZP/TFMPP with MDMA, often in the same tablet. As previously
observed with amphetamine designer drugs, marked toxicity can
occur when the drugs are combined at individually non-cytotoxic
concentrations (Dias da Silva et al., 2013a, 2013b, 2013c). Since
combinations of piperazine designer drugs have already been
implicated in human intoxications, further studies are needed not
only to clarify the mechanisms involved in the observed cytotoxic
effects of the isolated drugs but also to address the effects of such
drug combinations.
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